Literature DB >> 11724798

The identification, characterization, and distribution of guinea pig CCR4 and epitope mapping of a blocking antibody.

Louise A Jopling1, Ian Sabroe, David P Andrew, Tracey J Mitchell, You Li, Martin R Hodge, Timothy J Williams, James E Pease.   

Abstract

Th2 lymphocytes play a central role in the control and maintenance of allergic inflammation. The chemokine receptor CCR4 is preferentially expressed on the surface of Th2 lymphocytes polarised in vitro. However, CCR4 is found on the surface of a significant proportion of circulating memory T lymphocytes, some of which are capable of producing the Th1-associated cytokine interferon gamma. To investigate the function of CCR4 on guinea pig (gp) T lymphocytes, we identified the open-reading frame of gpCCR4, which encodes a 361-amino acid protein with 88 and 81% amino acid identity to human and murine CCR4 sequences, respectively. Cells transfected with gpCCR4 migrated toward the human and murine orthologues of the CCR4 ligands, macrophage-derived chemokine and thymus and activation-regulated chemokine. Surface expression of CCR4, using an anti-human CCR4 monoclonal antibody, 10E4, was detected on approximately 12% of guinea pig peripheral blood T helper cells, and CCR4(+) guinea pig thymocytes were detected in low numbers. However, CCR4(+) T helper cells constituted approximately 9% of the T lymphocyte population within the normal guinea pig lung and 52% of the guinea pig bronchoalveolar lavage fluid, which is consistent with a role for CCR4 in T lymphocyte development and trafficking through normal tissues. Subsequent analysis of chimeric chemokine receptors indicated that 10E4, a functional inhibitor of gpCCR4 responses, recognized the amino terminus of CCR4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724798     DOI: 10.1074/jbc.M109974200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.

Authors:  Jonathan M Viney; David P Andrew; Rhian M Phillips; Andrea Meiser; Pallavi Patel; Melissa Lennartz-Walker; David J Cousins; Nicholas P Barton; David A Hall; James E Pease
Journal:  J Immunol       Date:  2014-02-21       Impact factor: 5.422

2.  CCR4 blockade does not inhibit allergic airways inflammation.

Authors:  Dolores M Conroy; Louise A Jopling; Clare M Lloyd; Martin R Hodge; David P Andrew; Timothy J Williams; James E Pease; Ian Sabroe
Journal:  J Leukoc Biol       Date:  2003-07-15       Impact factor: 4.962

Review 3.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

4.  Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.

Authors:  De-Kuan Chang; Jianhua Sui; Shusheng Geng; Asli Muvaffak; Mei Bai; Robert C Fuhlbrigge; Agnes Lo; Anuradha Yammanuru; Luke Hubbard; Jared Sheehan; James J Campbell; Quan Zhu; Thomas S Kupper; Wayne A Marasco
Journal:  Mol Cancer Ther       Date:  2012-08-06       Impact factor: 6.261

Review 5.  Targeting chemokine receptors in disease--a case study of CCR4.

Authors:  Roberto Solari; James E Pease
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

6.  Screening of chemokine receptor CCR4 antagonists by capillary zone electrophoresis.

Authors:  Zhe Sun; Lin-Jie Tian; Qian Lin; Xiao-Mei Ling; Jun-Hai Xiao; Ying Wang
Journal:  J Pharm Anal       Date:  2011-10-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.